Panacea Acquisition II registered with the SEC to offer 15 million shares at $10 each. The offer does not include warrants.
Panacea II in the filing said it will concentrate on companies in the biotechnology sector in North America or Europe.
The SPAC is led by CEO and Chairman nominee Oleg Nodelman, who is the founder and portfolio manager of EcoR1, a biotech-focused investment advisory firm that invests in companies at all stages of research and development.
The SPAC intends to apply for a listing on the Nasdaq under PANA. Read more.
